

HU-M2011267 Seat No. _____

M. Pharm. (Sem. II) (CBCS) Examination

June / July - 2017

International Regulatory Requirements (Core IV)

Time: 3 Hours] [Total Marks: 80

Instructions: 1.

- 1. Answer any three from each section.
- 2. Question 1 and 5 are compulsory.
- 3. Answer and tie up both the sections separately.
- 4. Figures to the right indicates marks.
- 5. Draw neat and clean diagrams as required.

SECTION - I

- 1 Write any seven out of ten each carry 2 marks. $7\times2=14$
 - 1. What is IVIVC?
 - 2. Describe different types of labelling used in pharmaceuticals.
 - 3. Differentiate IND, NDA and ANDA.
 - 4. Describe investigator brochure (IB).
 - 5. Briefly describe over the counter products.
 - 6. Enlist different drug regulatory agencies of various countries.
 - 7. What is the importance of herbal drugs in under developed countries?
 - 8. Define marketing authorization.
 - 9. What is bioequivalence? Where it is needed to perform bioequivalence studies?
 - 10. What is the importance of post marketing surveillance?
- 2 1. Write a detailed note on Chemistry, Manufacturing 7 and Controls (CMC) of generic drug.
 - 2. Write a note on post approval changes of new drug application.

3	1.	Describe in detail Laboratory Information Management System (LIMS).	7
	2.	What are combination products? Describe all class in detail.	6
4	1.	Write a note on medical devices.	7
	2.	Describe in detail Hatch-Waxman Act.	6
		SECTION - II	
5	Write any two out of three each carry 7 marks. 2×7=14		
	1.	Describe the differences of CTD and eCTD in detail.	
	2.	Write a note on Contract Research Organization (CRO).	
	3.	Describe in detail Institutional Review Board/Independent	
		Ethics committee-formation and working procedures.	
6	1.	Describe the role of Quality Assurance (QA)	7
		department in clinical trials.	
	2.	Define the term investigators, sponsors and monitors.	6
7	1.	Describe how Indian agency regulates the clinical trials	. 7
	2.	Write a note on Health Insurance Portability and	6
		Ac countability Act of 1996.	
8	1.	Write a note on supplemental abbreviated new	7
		drug application.	
	2	Describe in detail investigation medicinal product dossier.	6